Articles dans des revues avec comité de lecture (78)
  1. 3. Jackson, D. J., Akuthota, P., Andradas, R., Bredenoord, A. J., Cordell, A., Gray, S., Kullman, J., Mathur, S. K., Pavord, I. D., Roufosse, F., Rubio, C., Rusek, I. C., Simon, D., Strobel, M. J., & Winders, T. (2023). Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases. Immunotherapy, 17, 10.2217/imt-2022-0312. doi:10.2217/imt-2022-0312
  2. 4. Valent, P., Klion, A. D., Roufosse, F., Simon, D., Metzgeroth, G., Leiferman, K. M., Schwaab, J., Butterfield, J. H., Sperr, W. R., Sotlar, K., Vandenberghe, P., Hoermann, G., Haferlach, T., Moriggl, R., George, T. I., Akin, C., Bochner, B. S., Gotlib, J., Reiter, A., Horny, H. P., Arock, M., Simon, H.-U., & Gleich, G. J. (2023). Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy, 78(1), 47-59. doi:10.1111/all.15544
  3. 5. Roufosse, F., Butterfield, J. H., Steinfeld, J., Bentley, J. J., von Maltzahn, R., Kwon, N., & Nelsen, L. (2023). Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome. Frontiers in Medicine, 10, 1035250. doi:10.3389/fmed.2023.1035250
  4. 6. Strobel, M. J., Alves, D., Roufosse, F., Antoun, Z., Kwon, N., Baylis, L. D., & Wechsler, M. M. (2022). Insights from Social Media on the Patient Experience of Living With Rare Eosinophil-Driven Diseases. Journal of patient experience, 9, 23743735221143953. doi:10.1177/23743735221143953
  5. 7. Rothenberg, M. E., Roufosse, F., Faguer, S., Gleich, G. J., Steinfeld, J., Yancey, S. W., Mavropoulou, E., Kwon, N., & HES Mepolizumab Study Group, (2022). Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5. The journal of allergy and clinical immunology. In practice, 10(9), 2367-2374.e3. doi:10.1016/j.jaip.2022.04.037
  6. 8. Chen, M., Roufosse, F., Wang, S. S., Verstovsek, S., Durrani, S. S., Rothenberg, M., Pongdee, T., Butterfield, J. H., Lax, T., Wechsler, M. M., Stein, M. L., Ogbogu, P. U., Kahwash, B. B., Mathur, S. S., Simon, D., Akuthota, P., Holland, N., Wetzler, L., Ware, J. A. J., Guo, C., Fay, M. M., Khoury, P., Klion, A., & Bochner, B. (2022). An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. Journal of Allergy and Clinical Immunology: In Practice. doi:10.1016/j.jaip.2022.02.006
  7. 9. Jackson, D. J., Akuthota, P., & Roufosse, F. (2022). Eosinophils and eosinophilic immune dysfunction in health and disease. European respiratory review : an official journal of the European Respiratory Society, 31(163). doi:10.1183/16000617.0150-2021
  8. 10. Jackson, D. J., Akuthota, P., Andradas, R., Bredenoord, A. J., Cordell, A., Gray, S., Kullman, J., Mathur, S. S., Pavord, I. D., Roufosse, F., Rubio, C., Rusek, I. C., Simon, D., Strobel, M. J., & Winders, T. (2022). Improving Care in Eosinophil-Associated Diseases: A Charter. Advances in therapy. doi:10.1007/s12325-022-02110-8
  9. 11. Gleich, G. J., Roufosse, F., Chupp, G., Faguer, S., Walz, B., Reiter, A., Yancey, S. W., Bentley, J. J., Steinfeld, J., & HES Mepolizumab Study Group, (2021). Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. The journal of allergy and clinical immunology. In practice, 9(12), 4431-4440.e1. doi:10.1016/j.jaip.2021.07.050
  10. 12. Catherine, J., & Roufosse, F. (2021). What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Seminars in Immunopathology, 2021, 1-20. doi:10.1007/s00281-021-00857-w
  11. 13. Jacobsen, E. A., Jackson, D. J., Heffler, E., Mathur, S. K., Bredenoord, A. J., Pavord, I. I., Akuthota, P., Roufosse, F., & Rothenberg, M. E. (2021). Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies. Annual review of immunology, 39, 719-757. doi:10.1146/annurev-immunol-093019-125918
  12. 14. Carpentier, C., Schandené, L., Dewispelaere, L., Heimann, P., Cogan, E., & Roufosse, F. (2021). CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited. Journal of Allergy and Clinical Immunology: In Practice. doi:10.1016/j.jaip.2021.01.030
    13. << Précédent 1 2 3 4 5 6 7 8 9 Suivant >>